FIELD: medicine.SUBSTANCE: invention relates to medicine, namely to cardiology and can be used to assess the risk of chronic heart failure in young men with arterial hypertension. Determining the cardiotrophin-1 plasma concentration. Determining the ratio of the maximum velocities of the transmittal blood flow at the beginning and end of the diastole (E/A) initially and at the height of hyperglycemia when an intravenous load by an individual standardized dose of glucose is administered. Calculating the value of the glucose-induced change in E/A as the modulus of the E/A difference, defined initially and at the height of hyperglycemia. If the value of the glucose-induced change in E/A is greater than or equal to 0.5, 1 point is awarded, less than 0.5 is 0 points. With a cardiotrophin-1 plasma concentration greater than or equal to 200 pg/ml, 1 point is awarded, less than 200 pg/ml 0 points are awarded. Summarizing the points. With a score of 2, a high risk of chronic heart failure developing is predicted. Wit
